Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04015895
Other study ID # 18CH176
Secondary ID 2018-A03310-55
Status Terminated
Phase
First received
Last updated
Start date December 4, 2019
Est. completion date June 12, 2023

Study information

Verified date February 2023
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Social inequalities in the face of cancer are significant in all countries. They are characterized by higher mortality among people may be in the lower socioeconomic category. The care pathway may also be a source of inequality or accentuate inequalities. Socially vulnerable patients must be provided with appropriate care. It is therefore necessary to identify patients with such social vulnerabilities as early as possible and to take them into account throughout the care process. To meet this need, the DEFCO project ("Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system") was designed and conducted by the Centre Hygée at the Lucien Neuwirth Cancer Institute (ICLN) in 2014 and 2015, in partnership with an industrial engineering research laboratory, the DISP ("Décision & Information pour les Systèmes de Production"). Its objective was to develop a tool for systematic screening of social fragility, involving few caregivers and making it possible to identify patients most at risk of social maladjustment. The choice was made to develop a self-administered questionnaire using tablets connected to a neural network. Since its implementation, the deployment of the DEFCO project ("Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system") tool at the Lucien Neuwirth Cancer Institute (ICLN) has required several training and awareness-raising activities to strengthen the motivation of the various stakeholders. These same actors have also implemented different strategies to optimize the functioning of the tool. Developed in a specialized institution, this tool must demonstrate, in this second stage of the project, it transferability and it possibilities of implementation in other structures. It is also necessary to evaluate it in terms of it is impact, particularly on the fluidity of care pathways and on the social consequences of the disease.


Description:

The aim of this study is to evaluate the implementation of the DEFCO ("Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system") social fragility tracking tool over one year.


Recruitment information / eligibility

Status Terminated
Enrollment 437
Est. completion date June 12, 2023
Est. primary completion date May 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient diagnosed for cancer (solid or hematological) since 15 days maximum - Age over 18 years - Affiliated with or entitled to a social security scheme Exclusion Criteria: - Refusal to participate - Patient unable to understand the study process - Patient with documented history of cognitive or psychiatric disorders. - Patient under tutorship or curatorship - Patient not understanding French

Study Design


Related Conditions & MeSH terms


Intervention

Other:
DEFCO tool
The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.

Locations

Country Name City State
France Centre Jean Perrin Clermont-Ferrand
France CH Emile Roux Le Puy-en-Velay
France Hospices Civils de Lyon - Lyon Sud Lyon
France Hospices Civils de Lyon, Centre Hospitalier Lyon Sud - Oncologie digestive Lyon
France Hospices Civils de Lyon, Groupement Hospitalier Est - Gynécologie Lyon
France Hospices Civils de Lyon, Groupement Hospitalier Nord - Gynécologie Lyon
France Chu Saint-Etienne Saint-Étienne
France Hôpital Privé de la Loire Saint-Étienne

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne Ligue contre le cancer, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Population reach Measured by number of actors who have been used DEFCO tool. Months: 12
Primary Population reach Measured by percentage of patient population included in relation to the target population. Months: 12
Primary Population reach Measured by rate of participation: number of patients included by physicians, proportion of patient who completed the tool, proportion of patients detected as socially fragile. Months: 12
Primary Tool adaptation by professionals Measured by number of tool variation according to centers. Months: 12
Primary Change from 6 months PACIC questionnaire result at 12 months Measured by comparison Patient Assessment of Chronic Illness Care Questionnaire (PACIC) by patient at 6 and 12 months after the inclusion.
Patient Assessment of Chronic Illness Care Questionnaire (PACIC) is a questionnaire which evaluates care during chronic illnesses with minimum score at 0 (bad care assessment) and maximum score at 130 (good care assessment).
Months: 6, 12
Primary Evaluation of effectiveness in real life by PPE Measured by comparison of Picker Patient Experience Questionnaire (PPE) between patients at 12 months after the inclusion.
Picker Patient Experience Questionnaire (PPE) is a questionnaire which measures the patient experience with minimum score at 0 (no problem with health care access) and maximum score at 100 (problem with health care access).
Months: 12
Primary Change from baseline FACT-G questionnaire result at 12 months Measured by comparison Functional Assessment of Cancer Therapy-General Questionnaire (FACT-G) by patient at the baseline and 12 months after.
Functional Assessment of Cancer Therapy-General Questionnaire (FACT-G) is a questionnaire which measures the quality of life of the patient with minimum score at 0 (low quality of life) and maximum score at 108 (high quality of life).
Months: 0, 12
Primary Change from baseline HAD questionnaire result at 12 months Measured evolution of Hospital Anxiety and Depression Questionnaire (HAD) at the baseline and 12 months after.
Hospital Anxiety and Depression Questionnaire (HAD) is a questionnaire which measures evolution of patient anxiety by 2 sub-scores :
Anxiety sub-score: with minimum score at 0 (no anxiety) and maximum score at 21 (anxiety)
Depression sub-score: with minimum score at 0 (no depression) and maximum score at 21 (depression)
Months: 0, 12
Primary Evaluation of practices effectiveness by using the tool Measured by proportion of patients who used the tool compared to patients who were included. Months: 12
Primary Evaluation of effectiveness of practices by Personalized Care Project Measured by number of social components integrated into the Personalized Care Project. Months: 24
Primary Evaluation of effectiveness of practices by identification of support systems Measured of number of support systems in each center. Months: 24
Primary Evaluation of effectiveness of practices by patient's satisfaction: questionnaire Measured by satisfaction questionnaire to the patient. Satisfaction questionnaire to the patient had 6 questions with minimum score at 0 (no contented) and maximum score at 18 (contented). Months: 12
Primary Evaluation of effectiveness of practices by caregiver's satisfaction offering the tool: questionnaire Measured by satisfaction questionnaire to the caregiver. Satisfaction questionnaire to the caregiver had 7 questions with minimum score at 0 (no contented) and maximum score at 21 (contented). Months: 24
Primary Maintenance and institutionalization Number of professionals made available for DEFCO tool. Months: 24
Primary Change from baseline interview with professional at 12 months Assessed by interviews with professionals who have used DEFCO tool. Interviews with professionals will be realized at the baseline and the end at the study. Months: 0, 24
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients